Last reviewed · How we verify
NCT04133116
A Study of LY3471851 in Healthy Participants
Phase 1 trial testing LY3471851 in Healthy in 36 participants. Completed in 6 March 2020.
6 March 2020
Quick facts
| Lead sponsor | Nektar Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 36 |
| Start date | 29 October 2019 |
| Primary completion | 6 March 2020 |
| Estimated completion | 6 March 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- LY3471851 — full drug profile →
- Placebo
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Nektar Therapeutics — full company profile →
Who can join
Adults 20 to 64, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is to explore the safety and tolerability of LY3471851 in healthy Japanese and Caucasian participants. The study will also estimate how much LY3471851 gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 7 weeks for each participant.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.
Raeber ME, Sahin D, Karakus U, Boyman O. · · 2023 · cited 139× · PMID 37004361 · DOI 10.1016/j.ebiom.2023.104539 -
IL-2-based approaches to Treg enhancement.
Harris F, Berdugo YA, Tree T. · · 2023 · cited 81× · PMID 36399073 · DOI 10.1093/cei/uxac105 -
"IL-2 immunotherapy for targeting regulatory T cells in autoimmunity".
Lykhopiy V, Malviya V, Humblet-Baron S, Schlenner SM. · · 2023 · cited 61× · PMID 37741949 · DOI 10.1038/s41435-023-00221-y -
Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus.
Fanton C, Furie R, Chindalore V, Levin R, et al · · 2022 · cited 26× · PMID 35517914 · DOI 10.1016/j.jtauto.2022.100152 -
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.
Silverberg JI, Rosmarin D, Chovatiya R, Bieber T, et al · · 2024 · cited 19× · PMID 39455575 · DOI 10.1038/s41467-024-53384-1 -
Immune cell aberrations in Systemic Lupus Erythematosus: navigating the targeted therapies toward precision management.
Wu Y, Zhang W, Liao Y, Sun T, et al · · 2025 · cited 11× · PMID 40524185 · DOI 10.1186/s11658-025-00749-z
Verify or expand the search:
- PubMed search for NCT04133116
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LY3471851
Trials testing the same drug.
- NCT05565729 — A Phase I Study of LY3471851 in Healthy Participants · Phase 1 · completed
- NCT04998487 — A Single-Dose Study of LY3471851 in Healthy Participants · Phase 1 · completed
- NCT04677179 — A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) · Phase 2 · terminated
- NCT04433585 — A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) · Phase 2 · completed
- NCT04081350 — A Study of LY3471851 in Participants With Eczema · Phase 1 · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Nektar Therapeutics trials
Trials by the same sponsor.
- NCT06136741 — A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopi · Phase 2 · active not recruiting
- NCT05664217 — NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma · Phase 2, PHASE3 · terminated
- NCT05565729 — A Phase I Study of LY3471851 in Healthy Participants · Phase 1 · completed
- NCT04969861 — BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) · Phase 2, PHASE3 · terminated
- NCT04998487 — A Single-Dose Study of LY3471851 in Healthy Participants · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04133116 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nektar Therapeutics
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04133116.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing